Last reviewed · How we verify
NCT06792955
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
Phase 1 trial testing HRS9531 injection in Overweight/Obesity in 120 participants. Completed in 6 June 2025.
6 June 2025
Quick facts
| Lead sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 11 February 2025 |
| Primary completion | 6 June 2025 |
| Estimated completion | 6 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- HRS9531 injection
- HRS9531 injection
Conditions studied
- Overweight/Obesity — all drugs for Overweight/Obesity →
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with Overweight/Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is being conducted to evaluate the bioequivalence between a single-dose pen and a multi-dose pen of HRS9531 injection solution.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06792955
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HRS9531 injection
Trials testing the same drug.
- NCT06654960 — Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects · Phase 1 · completed
- NCT06396429 — To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese · Phase 3 · completed
- NCT05966272 — Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects · Phase 2 · completed
- NCT05881837 — Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes · Phase 2 · completed
Other recruiting trials for Overweight/Obesity
Currently open trials in the same condition.
- NCT07428187 — Snacking Effects on the Brain Response to Foods and Satiety During Dieting · NA · recruiting
- NCT07505745 — MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity · Phase 2 · recruiting
- NCT07382908 — Bioequivalence Study of BGM0504 Injection · Phase 1 · recruiting
Other Fujian Shengdi Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT06855147 — Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects · Phase 1 · completed
- NCT06841445 — Efficacy and Safety of HRS9531 Tablet in Obese Subjects · Phase 2 · completed
- NCT06723691 — Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healt · Phase 1 · completed
- NCT06732154 — A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects · Phase 1 · completed
- NCT06654960 — Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06792955 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Shengdi Pharmaceutical Co., Ltd.
- Last refreshed: 12 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06792955.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing